BMY 8-K Current Reports
BRISTOL MYERS SQUIBB CO - 391 current reports
BRISTOL MYERS SQUIBB CO 8-K Report, Shareholder Vote Results (May 8, 2026)
Bristol Myers Squibb Company (BMY) held its Annual Meeting of Shareholders on May 5, 2026, as detailed in this 8-K filing. The meeting saw decisive votes on key corporate governance and executive matters. All 11 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and strategy. Furthermore, shareholders provided advisory approval for the compensation of named executive officers and ratified the company's 2026 stock award and incentive plan, signaling support for the company's incentive structures. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 received overwhelming ratification. However, a shareholder proposal advocating for an independent board chairperson was not approved, suggesting that the current governance structure, where the roles may be combined or held by a non-independent director, remains favored by the majority of shareholders at this time. Overall, the results reflect robust shareholder support for BMY's management, operational plans, and existing governance framework.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 30, 2026)
Bristol-Myers Squibb Company (BMY) has filed a Form 8-K on April 30, 2026, to report its financial results for the first quarter of 2026. The filing includes a press release detailing these results and a presentation on financial and operating initiatives, both of which are available on the company's website. Investors should note that the company is referencing non-GAAP financial information and provides reconciliations to GAAP measures within the furnished materials. This report serves as an announcement of the company's quarterly performance and strategic outlook. While specific financial figures are not detailed within the 8-K text itself, the furnished exhibits (Exhibit 99.1 and 99.2) are the primary sources for understanding BMY's performance and forward-looking statements for the first quarter of 2026. Investors are encouraged to review these exhibits for comprehensive details on revenue, profitability, and any strategic updates shared during the associated conference call.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 5, 2026)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 5, 2026, to announce its financial results for the fourth quarter and full year of 2025. The filing includes a press release (Exhibit 99.1) detailing these results and a presentation (Exhibit 99.2) covering financial and operating initiatives. Investors should refer to these documents, available on the company's website, for a comprehensive understanding of BMY's recent performance and strategic direction. Both the press release and presentation reference non-GAAP financial information. The company emphasizes that reconciliations between non-GAAP and GAAP measures, along with explanations for the use of non-GAAP figures, are provided within the press release. Investors are advised to review these reconciliations carefully when evaluating the company's financial health and operational efficiency.
BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 12, 2026)
Bristol-Myers Squibb Company (BMY) has filed a Form 8-K on January 12, 2026, to disclose an investor presentation made available on their website on January 11, 2026. This presentation, attached as Exhibit 99.1, is intended to provide updates and insights to investors regarding the company's strategic direction, performance, and future outlook. While the filing itself does not contain new financial results or material events beyond the presentation, it serves as a crucial communication channel for investors seeking the latest information directly from the company. Investors are encouraged to review the presentation for details on BMY's ongoing initiatives, pipeline updates, and market positioning, as this is the primary vehicle through which the company is sharing this information in connection with this filing.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 18, 2025)
Bristol Myers Squibb Company (BMY) has filed an 8-K report detailing the results of its previously announced cash tender offers for its outstanding notes. The company announced early participation results on November 17, 2025, and on November 18, 2025, it released the accepted amounts and pricing terms of these offers. These tender offers are part of a strategy to manage its debt obligations, with full details provided in the Offer to Purchase document dated November 3, 2025. Investors should note that this filing primarily concerns debt management and does not represent an offer to buy or sell equity securities. The early participation results and final pricing indicate the company's progress in its debt restructuring efforts, which could impact its financial leverage and interest expense going forward. The full financial implications will be clearer as the settlement process concludes and is reflected in future financial statements.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 10, 2025)
Bristol Myers Squibb Company (BMY) has announced the successful completion of a significant public offering of €5.00 billion in aggregate principal amount of senior unsecured notes, issued by its wholly-owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. The offering comprises notes with maturities ranging from 2030 to 2055 and interest rates from 2.973% to 4.581%. These notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company. The primary purpose of this capital raise is to fund the company's tender offer to repurchase various series of its outstanding notes, as well as to cover associated fees and expenses. Any remaining proceeds will be allocated for general corporate purposes. This debt issuance signifies a strategic move by Bristol Myers Squibb to manage its existing debt obligations and optimize its capital structure.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 3, 2025)
Bristol-Myers Squibb Company (BMY) has announced the initiation of cash tender offers to repurchase up to $7 billion of its outstanding notes. This move suggests the company is actively managing its debt obligations, potentially aiming to optimize its capital structure or take advantage of favorable market conditions for debt buybacks. Investors should note that this tender offer is a significant financial maneuver that could impact the company's liquidity and leverage ratios. The details of the offer, including pricing and specific notes targeted, are outlined in the company's Offer to Purchase dated November 3, 2025. The aggregate purchase price is capped at $7 billion, with further limitations specified for different note pools.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 30, 2025)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 30, 2025, to announce its financial results for the third quarter of 2025. The filing primarily includes a press release detailing these results and a presentation covering financial and operating initiatives discussed during the company's conference call. Investors should review these furnished documents for a comprehensive understanding of BMY's performance and strategic direction. The company has made available both the Earnings Press Release and the Bristol Myers Presentation on its website. These materials contain forward-looking information, including references to non-GAAP financial measures. BMY has also provided reconciliations for these non-GAAP figures to their comparable GAAP counterparts, which are crucial for investors seeking to interpret the financial performance accurately. It is important to note that this information is furnished and not considered "filed" under the Securities Exchange Act, meaning it does not carry the same liability implications as formally filed documents, but it is still material for investment decisions.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 31, 2025)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on July 31, 2025, to disclose its financial results for the second quarter of 2025. The filing primarily serves to furnish the earnings press release and a related presentation, both of which are available on the company's website. These documents contain detailed financial performance information, including both GAAP and non-GAAP measures, which investors should review for a comprehensive understanding of the company's operational and financial condition during the quarter. The earnings press release and presentation provide crucial insights into BMY's performance, strategic initiatives, and outlook. Investors are encouraged to access these furnished exhibits for specifics on revenue, profitability, and any forward-looking statements or strategic developments discussed. The company has also highlighted that reconciliations between GAAP and non-GAAP figures are available within these provided materials.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Jul 25, 2025)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the departure of Dr. Samit Hirawat, Chief Medical Officer and Head of Development. Dr. Hirawat will transition to an advisory role effective August 1, 2025, and will depart the company by November 1, 2025. This change in key leadership, particularly in the development function, may warrant investor attention as it could impact the company's research and development pipeline and strategic direction. In connection with his departure, Dr. Hirawat is entitled to standard severance benefits, pro-rated vesting of certain equity awards (Market Share Units and Performance Share Units), and a prorated annual incentive payout for 2025. The details of his compensation package are outlined in accordance with the company's established plans and agreements. Investors should monitor any future disclosures for updates on leadership transitions and their potential implications for BMY's operational and financial performance.
BRISTOL MYERS SQUIBB CO 8-K Report, Shareholder Vote Results (May 7, 2025)
Bristol Myers Squibb Co. (BMY) held its Annual Meeting of Shareholders on May 6, 2025, as detailed in this 8-K filing. The meeting's primary outcomes revolved around shareholder votes on key corporate governance and executive matters. Notably, all 11 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and oversight. The company also received shareholder approval for the compensation of its named executive officers through an advisory vote, suggesting alignment between executive pay and shareholder interests. Furthermore, shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2025. In contrast, two shareholder proposals, one concerning Corporate Financial Sustainability and another requesting the cessation of DEI (Diversity, Equity, and Inclusion) Efforts, did not receive sufficient support to pass. These results reflect shareholder sentiment on strategic priorities and corporate social responsibility initiatives.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 24, 2025)
Bristol Myers Squibb Company (BMY) has filed an 8-K report on April 24, 2025, primarily to announce its first-quarter 2025 financial results and provide related presentations. The filing includes an Earnings Press Release (Exhibit 99.1) and a Bristol Myers Presentation (Exhibit 99.2), both dated April 24, 2025, detailing the company's performance and strategic initiatives for the period. Investors should note that both documents contain references to non-GAAP financial information, with reconciliations provided in the Earnings Press Release. This report serves as the formal vehicle for disseminating BMY's Q1 2025 financial outcomes and outlook. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished exhibits for a comprehensive review of operational and financial conditions. The company also highlights that the information provided under Regulation FD is furnished and not deemed 'filed' for certain regulatory purposes, and they reserve the right to remove the presentation from their website.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Feb 18, 2025)
Bristol Myers Squibb Company (BMY) has filed an 8-K report announcing the upcoming retirement of Sandra Leung, Executive Vice President and General Counsel. Ms. Leung intends to retire in 2025 and will remain with the company for a transition period to ensure a smooth handover of her responsibilities. This change in a key executive role warrants investor attention as leadership transitions can sometimes impact strategic direction and operational continuity. Ms. Leung is eligible for retirement benefits under the company's existing compensation plans. While the report does not detail the specific benefits, it confirms adherence to established policies. Investors should monitor future filings for announcements regarding Ms. Leung's successor, as the appointment of a new General Counsel is a significant development for the company's legal and governance framework.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 6, 2025)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 6, 2025, to announce its financial results for the fourth quarter and full year of 2024. The filing includes a press release detailing these results, which investors should review for a comprehensive understanding of the company's performance. This report also references a supplemental presentation available on the company's website, offering further insights into financial and operational initiatives. Investors should note that both the press release and presentation contain non-GAAP financial measures, with reconciliations provided in the press release. This 8-K serves as a notification and furnishing of material information, rather than a definitive filing with liabilities under Section 18 of the Exchange Act, for the information furnished under Item 7.01. The company's decision to make the presentation available on its website is subject to change. Investors seeking detailed financial performance, strategic updates, and forward-looking statements will find the most crucial information within the furnished press release and presentation materials.
BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 13, 2025)
Bristol-Myers Squibb Company (BMY) filed a Current Report on Form 8-K on January 13, 2025, to disclose the posting of an investor presentation on its website. This presentation, dated January 13, 2025, is attached as Exhibit 99.1 to the filing and is available on the company's investor relations website. The filing itself does not contain substantive new financial information but serves to make the investor presentation publicly accessible in accordance with Regulation FD. Investors should note that this filing is primarily a notification of available information rather than a report of material events or financial results. The attached investor presentation is expected to contain the most recent updates, strategic insights, and potentially forward-looking statements from the company. While the information furnished is not deemed "filed" for regulatory purposes, it is important for investors seeking the latest company communications.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 31, 2024)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 31, 2024, to announce its third-quarter 2024 financial results. The report primarily serves to furnish a press release detailing these results and a supplementary presentation that was made available during the company's earnings conference call. Investors should refer to the press release (Exhibit 99.1) for the specific financial and operational performance of the company during the third quarter. The company also notes that both the press release and the presentation contain non-GAAP financial information. Reconciliations of these non-GAAP measures to their nearest GAAP equivalents, along with explanations for their use, are provided within the furnished press release. Investors are advised to review these materials in conjunction with the press release to gain a comprehensive understanding of BMY's reported performance and strategic updates.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 26, 2024)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on July 26, 2024, to announce its financial results for the second quarter of 2024. The report primarily references an Earnings Press Release and a related Investor Presentation, both dated July 26, 2024, which contain detailed financial and operational information. Investors should refer to these furnished documents for a comprehensive understanding of the company's performance during the quarter. The company has made these materials available on its website and through a conference call and webcast. It's important for investors to note that both the press release and presentation include non-GAAP financial information. The company has provided reconciliations between non-GAAP and GAAP measures within the Earnings Press Release, along with explanations for the use of these non-GAAP figures. Investors are advised to review these reconciliations and the company's official filings for complete financial transparency.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Jun 18, 2024)
Bristol-Myers Squibb Company (BMY) announced a key addition to its Board of Directors, electing Michael R. McMullen as a new member effective July 1, 2024. This appointment increases the Board's size to eleven members. Mr. McMullen brings extensive executive leadership experience, notably as the former CEO of Agilent Technologies, where he significantly grew the company's market capitalization and drove operational and cultural transformations. His background in leading global operations and a proven track record of delivering shareholder returns are expected to be valuable assets to BMY. Furthermore, Mr. McMullen's expertise will be leveraged as he joins the Audit Committee of the Board. His compensation for board service aligns with the company's standard arrangements for non-employee directors, including an annual retainer and deferred share units. The company also noted the independence of Mr. McMullen under NYSE listing standards and its own board standards, with no disclosed arrangements or related party transactions influencing his appointment.
BRISTOL MYERS SQUIBB CO 8-K Report, Bylaw Amendment (May 9, 2024)
Bristol-Myers Squibb Company (BMY) filed an 8-K report detailing the outcomes of its Annual Meeting of Shareholders held on May 7, 2024. The most significant event for investors is the shareholder approval of an amendment to the company's Certificate of Incorporation. This amendment, effective May 7, 2024, aims to eliminate or limit the monetary liability of specified executive officers for breaches of the duty of care. This change in governance structure could impact executive decision-making and the company's overall risk profile. In addition to the liability amendment, the report indicates that shareholders overwhelmingly re-elected all 10 director nominees, approved the compensation of named executive officers on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2024. Conversely, two shareholder proposals—one advocating for an independent Board Chairperson and another for adopting a Board policy on executive retention of significant stock—did not receive majority approval.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 25, 2024)
Bristol-Myers Squibb Company (BMY) filed an 8-K on April 25, 2024, primarily to announce its first quarter 2024 financial results. The filing includes a press release detailing these results and a presentation discussing financial and operational initiatives. Investors should note that both the press release and presentation contain non-GAAP financial information, with reconciliations provided in the press release. This report serves as a formal notification of the Q1 2024 performance and provides supplementary materials for a deeper understanding of the company's financial standing and strategic direction. The company has made these materials available on its website and through a webcast, allowing investors to access detailed financial data and management's commentary on the quarter's performance and outlook.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Mar 18, 2024)
Bristol-Myers Squibb Company (BMY) has announced the successful completion of its acquisition of Karuna Therapeutics, Inc. (Karuna) as of March 17, 2024. This strategic move involves BMY acquiring all outstanding shares of Karuna common stock for a cash payment of $330.00 per share, excluding certain specified shares. The transaction represents a significant investment by BMY in Karuna's pipeline and potential. Investors should note that this acquisition marks a pivotal step for Bristol-Myers Squibb, signaling its commitment to expanding its therapeutic areas, likely focusing on Karuna's specialized drug development programs. The financial implications of this $330 per share cash transaction will be reflected in BMY's future financial statements, and further details on the integration and impact are anticipated.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Mar 18, 2024)
Bristol Myers Squibb Company (BMY) announced a change in its Board of Directors composition. Gerald Storch has informed the Board that he will not seek re-election at the upcoming 2024 Annual Meeting of Shareholders, scheduled for May 7, 2024. This decision means Mr. Storch will step down from his board position after this meeting. Following this departure, the Board has decided to reduce its size from its current number to ten directors, effective immediately after the 2024 Annual Meeting. Investors should monitor any further announcements regarding director nominations or changes in board committee memberships, as these can sometimes signal strategic shifts or governance considerations, though the primary impact here appears to be a routine board refreshment.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 22, 2024)
Bristol Myers Squibb Company (BMY) announced the completion of a significant public offering of debt securities, raising a total of $11.75 billion. This offering includes a variety of notes with fixed and floating interest rates, maturing between 2026 and 2064. The primary purpose of these proceeds is to fund the cash consideration for the proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., along with associated fees and expenses. Any remaining net proceeds will be used for general corporate purposes. The offering was completed as planned, irrespective of the acquisition closings. However, the indenture includes provisions for a Special Mandatory Redemption for most of the notes if the Karuna acquisition is not consummated by specific deadlines or if BMY decides not to pursue it. This offers a degree of protection to noteholders in the event the acquisitions do not proceed, with a redemption price of 101% of the principal amount plus accrued interest.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Feb 15, 2024)
Bristol Myers Squibb Company (BMY) announced a key leadership change within its finance department. Effective February 15, 2024, Phil Holzer has been appointed as the new Senior Vice President and Controller. Mr. Holzer brings extensive experience to this role, having been with the company since 2001 and most recently serving as Senior Vice President, Finance, Treasury and Tax Operations since 2021. This appointment signifies a transition as the current Senior Vice President and Controller, Ms. Sharon Greenlees, will be moving to another role within the company. Investors should view this as a normal course of business succession planning. Mr. Holzer's long tenure and diverse financial leadership positions within BMY suggest a stable internal promotion, which typically indicates continuity in financial strategy and operations. The filing also notes that Mr. Holzer is not involved in any reportable related-party transactions or arrangements related to his appointment.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 14, 2024)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report primarily to address an unsolicited "mini-tender" offer from Tutanota LLC. Tutanota is attempting to purchase a small percentage of BMY's outstanding shares (less than 0.025%) at a price of $55.00 per share. The company explicitly states it does not endorse this offer and advises its shareholders not to tender their shares. This action is a protective measure for shareholders, aiming to prevent them from accepting an offer that is likely significantly below the market value of BMY stock and potentially subject to unfavorable terms. Investors should be aware that this 8-K filing is a cautionary announcement, not an indication of significant company performance or strategic shifts. The unsolicited offer is from a third party and is not associated with Bristol-Myers Squibb. The company's recommendation against tendering shares suggests that shareholders who accept this offer may be selling their stock at a discount. Shareholders who have already tendered are advised to consider withdrawing their shares before the offer's expiration on February 23, 2024.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 2, 2024)
Bristol Myers Squibb Company (BMY) filed an 8-K on February 2, 2024, to announce its financial results for the fourth quarter and full year of 2023. The filing primarily includes the press release detailing these results (Exhibit 99.1) and a supporting presentation (Exhibit 99.2), both of which were made available on February 2, 2024. These documents provide key financial and operational updates for investors to assess the company's performance. The company is utilizing this 8-K filing to furnish the earnings press release and presentation materials, which contain both GAAP and non-GAAP financial information. Investors are directed to the press release for reconciliations between these measures. The filing itself does not introduce new material events beyond the financial results announcement, but investors should review the furnished exhibits for a comprehensive understanding of BMY's 2023 performance and outlook.
BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 8, 2024)
Bristol-Myers Squibb Company (BMY) filed an 8-K report on January 8, 2024, primarily to disclose an investor presentation that was posted on their website on the same date. This presentation is available as an exhibit to the filing. While this filing does not contain new financial results or significant business updates beyond the presentation, it serves as a channel for the company to communicate with its investors and the market. Investors should review the attached presentation for any information or insights Bristol-Myers Squibb is providing to the investment community regarding its business, strategy, or outlook.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Dec 22, 2023)
Bristol-Myers Squibb Company (BMY) announced on December 22, 2023, that it has entered into a definitive agreement to acquire Karuna Therapeutics, Inc. (Karuna) for $330.00 per share in cash. This transaction represents a significant strategic move for BMY, aiming to bolster its neuroscience pipeline with Karuna's promising drug candidate, KarXT, for treating schizophrenia and other neurological disorders. The acquisition is structured as a merger, with Karuna surviving as a wholly-owned subsidiary of BMY. The deal is subject to customary closing conditions, including the approval of Karuna's stockholders. Investors should monitor regulatory approvals and the timeline for closing, as well as the integration of Karuna's assets into BMY's portfolio, which could significantly impact future growth and product offerings.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 13, 2023)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the successful completion of a substantial public offering of notes totaling $4.5 billion. The offering comprises four tranches with varying interest rates and maturity dates, ranging from 2031 to 2063. The company intends to utilize the net proceeds from this offering for general corporate purposes, with a specific mention of financing the proposed acquisition of Mirati Therapeutics, Inc., and associated fees and expenses. This issuance represents a strategic move to secure funding for significant future investments and operational needs. The notes are governed by an indenture, which includes customary covenants and restrictions related to incurring secured debt, engaging in sale/leaseback transactions, and significant corporate actions like mergers. The company retains the option to redeem the notes prior to maturity, with redemption terms outlined for both 'make-whole' provisions before a certain date and at par value on or after the applicable 'Par Call Date.' Investors should note the specific interest rates and maturity dates, as well as the company's flexibility in early redemption.
BRISTOL MYERS SQUIBB CO 8-K/A Report, Executive Changes (Oct 31, 2023)
This 8-K/A filing from Bristol Myers Squibb (BMY) provides an update on leadership transitions and associated compensation, primarily concerning the CEO role. Effective November 1, 2023, Dr. Christopher Boerner will assume the CEO position, taking over from Dr. Giovanni Caforio, who will transition to Executive Chairman. This amendment clarifies that Dr. Caforio will not stand for re-election to the Board and will retire on April 1, 2024, at which point Dr. Boerner will also assume the role of Chairman of the Board. The filing details Dr. Boerner's new compensation package as CEO, including a base salary of $1,500,000, a target bonus of 150% of base salary, and additional long-term incentive awards valued at $1,600,000. Dr. Caforio's compensation remains unchanged during his transition to Executive Chairman, but he will not receive further long-term incentive awards. Investors should note the structured handover and the confirmation of Dr. Boerner's leadership into the Chairman role.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 26, 2023)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 26, 2023, to announce its third-quarter 2023 financial results. The filing primarily includes a press release detailing these results and a related presentation shared during their earnings conference call. Investors should note that the company is referencing non-GAAP financial information, and reconciliations to GAAP measures are available in the furnished press release. While the specific financial figures are not detailed within this 8-K, the furnishing of the press release and presentation indicates that BMY has disclosed its Q3 performance and strategic updates. Investors are encouraged to review Exhibit 99.1 (Earnings Press Release) and Exhibit 99.2 (Bristol Myers Presentation) for the complete financial details, key performance indicators, and forward-looking statements.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Aug 10, 2023)
Bristol-Myers Squibb Company (BMY) announced on August 9, 2023, that it has entered into accelerated share repurchase (ASR) agreements to buy back an aggregate of $4.0 billion of its common stock. These transactions are part of a previously authorized multi-year share repurchase program and are being executed with major financial institutions including Bank of America, Citibank, JPMorgan Chase, and Morgan Stanley. The ASR transactions are designed to return capital to shareholders and reflect the company's confidence in its financial position and future prospects. While an initial portion of the shares will be delivered promptly, the final number of shares repurchased will be determined by volume-weighted average prices over the repurchase period, with potential adjustments. This move is a significant capital allocation decision that investors will want to monitor for its impact on earnings per share and overall shareholder value.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 27, 2023)
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 27, 2023, to report its second quarter 2023 financial results and related presentations. While the filing itself does not contain the detailed financial figures, it directs investors to an accompanying press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for comprehensive information on the company's performance. These documents, available on the company's website, are crucial for understanding BMY's operational and financial standing for the period. Investors should note that the press release and presentation include non-GAAP financial measures, with reconciliations provided in the press release. The company has furnished these documents under Items 2.02 and 7.01, meaning they are not considered officially "filed" for purposes of Section 18 of the Exchange Act but are important for understanding the company's disclosed results and forward-looking initiatives.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (May 4, 2023)
Bristol Myers Squibb Company (BMY) announced significant leadership changes and reported the outcomes of its Annual Meeting of Shareholders held on May 2, 2023. The most notable development is the appointment of Dr. Christopher Boerner as Chief Operating Officer effective April 26, 2023, and his subsequent appointment as Chief Executive Officer effective November 1, 2023. Dr. Boerner has also been elected to the Board of Directors, increasing its size to twelve members. While he is a key executive, the Board has determined he is not independent under NYSE standards and will not serve on any Board committees, nor will he receive compensation for his director role. The Annual Meeting also saw shareholders re-elect all eleven incumbent directors, approve the compensation of named executive officers on an advisory basis, and vote for an annual advisory vote on executive compensation. Additionally, Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2023. However, shareholder proposals regarding an independent Board Chairperson and improvements to special shareholder meetings did not pass.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 27, 2023)
Bristol-Myers Squibb Company (BMY) filed an 8-K on April 27, 2023, to report its financial results for the first quarter of 2023. The filing includes a press release detailing the company's performance and a presentation on financial and operating initiatives. Investors should note that these releases contain both GAAP and non-GAAP financial information, with reconciliations provided in the press release. The primary purpose of this 8-K is to formally disseminate BMY's Q1 2023 financial outcomes and strategic updates. While the filing itself does not contain new operational data, it directs readers to the furnished exhibits for detailed financial figures and forward-looking discussions. Investors are encouraged to review these attached documents for a comprehensive understanding of the company's recent financial condition and performance.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Apr 26, 2023)
Bristol Myers Squibb Company (BMY) announced a significant leadership transition, with current Chairman and CEO Giovanni Caforio, M.D., set to retire as CEO on November 1, 2023. Dr. Caforio will remain Chairman until his CEO retirement and then transition to Executive Chairman for a period to be determined. This marks the end of an era for a key figure in the company's recent history. Following this announcement, the Board of Directors appointed Christopher Boerner, Ph.D., as the new Chief Executive Officer, effective November 1, 2023. Dr. Boerner, currently serving as Chief Operating Officer, has been with BMY since 2015 and has held various senior leadership roles, including Executive Vice President and Chief Commercialization Officer. His appointment signals a move towards internal succession for the top leadership role.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 28, 2023)
Bristol-Myers Squibb Company (BMY) filed an 8-K report on February 27, 2023, to provide an update regarding Contingent Value Rights (CVRs) associated with the 2019 acquisition of Celgene Corporation. The report specifically addresses the Abraxane® product and its related CVRs. Investors should note that the Company has notified the Trustee that the net sales for Abraxane in the year ended December 31, 2022, did not meet the threshold required for a Net Sales Payment under the CVR Agreement. This notification is significant as it confirms no immediate payout is due to CVR holders based on 2022 performance. The CVRs were tied to specific pipeline products of Celgene, including Abraxane, acquired as part of the broader Celgene integration. While this filing addresses the 2022 performance, BMY retains the right to disclose future Net Sales Payments if subsequent performance metrics are met and disclosed on their investor website.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 2, 2023)
Bristol Myers Squibb (BMY) has filed an 8-K report on February 2, 2023, to announce its financial results for the fourth quarter and full year of 2022. The report primarily directs investors to accompanying press releases, supplemental information, and presentations available on the company's website for detailed financial and operational insights. This filing serves as a formal notification of the release of these results, allowing investors to access comprehensive data regarding the company's performance. Investors are encouraged to review the furnished exhibits, including the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2), which contain the core financial figures and reconciliations for non-GAAP measures. Additionally, the Bristol Myers Presentation (Exhibit 99.3) offers further context on financial and operating initiatives. It's important to note that the information furnished under Regulation FD is not considered 'filed' for legal liability purposes under Section 18 of the Exchange Act, but it provides crucial data for investment decision-making.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Jan 31, 2023)
Bristol Myers Squibb Company (BMY) has filed an 8-K report on January 30, 2023, announcing the departure of Dr. Rupert Vessey, Executive Vice President of Research and Early Development, effective July 3, 2023. This executive transition marks a notable change in the company's research leadership. While Dr. Vessey's departure is confirmed, the company has outlined the financial and equity arrangements associated with his exit. Investors should note the specific details regarding Dr. Vessey's severance benefits, which will be in line with the company's Senior Executive Severance Plan. Additionally, his equity awards, including Market Share Units (MSUs) and Performance Share Units (PSUs), will vest on a pro-rated basis. Notably, his 2019 Restricted Stock Units Inducement Award will vest in full. He will also receive a pro-rated annual incentive payout for 2023. These details provide transparency on the financial implications of this executive departure.
BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 9, 2023)
Bristol-Myers Squibb Company (BMY) filed an 8-K report on January 9, 2023, primarily to disclose an investor presentation that was posted on their website. This presentation, dated January 9, 2023, and attached as Exhibit 99.1 to the filing, is the key piece of information for investors. While the filing itself doesn't contain new financial results or material business updates beyond the presentation, it signifies the company's proactive engagement with investors and provides a platform for them to communicate strategic updates, pipeline developments, or financial outlook. Investors should review the linked investor presentation for the most current insights into BMY's business strategy, key performance indicators, and future expectations. The 8-K filing serves as a notification of this communication, emphasizing the importance of the information contained within the supplemental presentation. It's crucial to note that the information in this 8-K and its exhibit is not considered 'filed' for regulatory liability purposes under Section 18 of the Exchange Act, but it's essential for understanding the company's investor relations activities.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 26, 2022)
Bristol-Myers Squibb Company (BMY) filed an 8-K on October 26, 2022, to report its financial results for the third quarter of 2022. The filing primarily references a press release issued on October 25, 2022, which contains the detailed financial performance for the quarter. Investors should refer to this press release and accompanying supplemental information for specific figures regarding revenue, earnings, and other key financial metrics. Additionally, the report includes a presentation made on October 26, 2022, which discusses financial and operating initiatives. This presentation, along with the earnings press release and supplemental information, should be reviewed together to gain a comprehensive understanding of the company's recent performance and strategic direction. Notably, the company utilizes non-GAAP financial information, and reconciliations to GAAP measures are provided in the supplemental materials.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 27, 2022)
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 27, 2022, to report its financial results for the second quarter of 2022. The filing includes the earnings press release, supplemental financial information, and a presentation that was discussed during their investor conference call. While the specific financial figures are not detailed within the 8-K itself, these accompanying documents are crucial for investors to understand the company's performance, strategic initiatives, and outlook. Investors should review the furnished exhibits, particularly the Earnings Press Release and Supplemental Information, to gain insights into BMY's revenue, profitability, and any forward-looking statements. The presentation material provides further context on financial and operating initiatives. It's important to note that some of the presented information may be non-GAAP, and reconciliations to GAAP measures are available in the supplemental information.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Jun 15, 2022)
Bristol-Myers Squibb Company (BMY) announced an addition to its Board of Directors with the election of Dr. Deepak L. Bhatt, effective June 14, 2022. The Board's size has been expanded to eleven members to accommodate this appointment. Dr. Bhatt brings extensive experience in cardiovascular medicine, including over 20 years in acute coronary syndromes, preventive cardiology, and interventional techniques. His background includes significant leadership roles at major medical institutions such as Brigham and Women's Hospital, Harvard Medical School, and the Cleveland Clinic, as well as extensive involvement in cardiovascular clinical trials. This strategic appointment is notable for investors as it brings a highly respected medical expert onto the Board, likely strengthening the company's scientific and technological oversight, particularly in areas relevant to BMY's pharmaceutical focus. Dr. Bhatt's independence has been confirmed, and he will serve on the Science and Technology Committee. His compensation aligns with the company's standard director compensation structure.
BRISTOL MYERS SQUIBB CO 8-K Report, Shareholder Vote Results (May 5, 2022)
This 8-K filing from Bristol Myers Squibb (BMY) reports the outcomes of their Annual Meeting of Shareholders held on May 3, 2022. The primary focus for investors is the shareholder voting results on key corporate governance and compensation matters. Notably, all 10 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board leadership. The "say-on-pay" advisory vote to approve the compensation of named executive officers also passed with a significant majority, suggesting general shareholder acceptance of the company's executive compensation practices.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 29, 2022)
Bristol Myers Squibb (BMY) has filed an 8-K report on April 29, 2022, detailing their financial results for the first quarter of 2022. The report primarily serves to furnish the company's earnings press release and supplemental financial information, which were made public on the same date. Investors should note that this filing is informational, providing access to the detailed Q1 2022 financial performance and operational updates presented by the company. The filing incorporates by reference the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2) which contain the core financial data. Additionally, a presentation (Exhibit 99.3) shared during the Q1 2022 earnings call is included, offering insights into financial and operating initiatives. While the presentation includes non-GAAP financial measures, reconciliations to GAAP are available in the supplemental information.
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 18, 2022)
Bristol-Myers Squibb (BMY) announced a modification to its non-GAAP financial reporting, effective Q1 2022, in response to SEC feedback. The company will now include significant R&D charges and other income related to upfront or contingent milestone payments from asset acquisitions and intellectual property licensing within its non-GAAP results. These items will be presented in a new financial statement line item called 'Acquired IPRD'. Prior period results will be restated to reflect this new presentation, providing investors with a more consistent view of these specific costs. The company provided a preliminary estimate that these Acquired IPRD charges and licensing income will have a net negative impact of approximately $0.10 per share on both GAAP and non-GAAP diluted earnings per share for the first quarter of 2022. Investors should note that the Q1 2022 results are not yet finalized and are subject to closing procedures, meaning the actual impact could differ from this estimate. This change aims to enhance transparency and comparability in the company's financial disclosures.
BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Mar 17, 2022)
Bristol Myers Squibb Company (BMY) has announced a change in its principal officer role for Senior Vice President and Controller. Effective April 25, 2022, Sharon Greenlees will assume this position, succeeding Karen Murphy Santiago, who will depart the company by May 1, 2022. Ms. Greenlees brings extensive financial experience from her recent role at AbbVie Inc. as Vice President and Controller, R&D Finance and Operations, and prior positions including Head of Supply Chain Finance and Vice President of Investor Relations. This executive transition in a key financial leadership role is the primary focus of this 8-K filing. Investors should note that Ms. Greenlees has a strong background in accounting and is a Certified Public Accountant. The filing also confirms that there are no undisclosed arrangements, understandings, family relationships, or related-party transactions concerning Ms. Greenlees's appointment, indicating a standard executive onboarding process.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Mar 3, 2022)
Bristol Myers Squibb Company (BMY) announced on March 1st and 2nd, 2022, updates regarding their previously announced cash tender offers to purchase outstanding notes. These offers encompass notes issued by BMY itself and its wholly-owned subsidiary, Celgene Corporation. The company has provided early participation results and announced an upsizing of these offers, indicating a proactive approach to managing its debt obligations. Furthermore, BMY has confirmed the early settlement and the accepted amounts along with the pricing terms for these tender offers. This move suggests that the company is taking advantage of favorable market conditions or strategic financial management to refinance or reduce its debt. Investors should note that these tender offers are governed by the terms outlined in the Offer to Purchase dated February 15, 2022, and any subsequent amendments.
BRISTOL MYERS SQUIBB CO 8-K Report, Material Agreement (Mar 2, 2022)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the completion of a significant public offering of senior unsecured notes. The offering, which closed on March 2, 2022, raised a total of $6 billion across four tranches with varying maturity dates and interest rates: $1.75 billion in 2.950% notes due 2032, $1.25 billion in 3.550% notes due 2042, $2 billion in 3.700% notes due 2052, and $1 billion in 3.900% notes due 2062. These notes were issued under an indenture that includes customary covenants and restrictions related to debt, sale/leaseback transactions, and mergers. The proceeds from this substantial debt issuance likely aim to support the company's strategic objectives, which could include funding acquisitions, research and development, or refinancing existing debt. Investors should note the specific interest rates and maturity dates for each tranche, as well as the company's option to redeem the notes under certain conditions before their maturity, particularly at a premium ("make-whole" provisions) prior to specified call dates, and at par thereafter. This move signals a proactive approach to managing its capital structure and financing future growth initiatives.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 24, 2022)
Bristol Myers Squibb (BMY) has filed an 8-K detailing the payment of contingent value rights (CVRs) related to the 2019 acquisition of Celgene Corporation. The filing specifically addresses the net sales of Abraxane for the year ended December 31, 2021, which triggered a payment to CVR holders. This payment reflects the ongoing financial obligations tied to the significant Celgene acquisition. Investors should note that the company has calculated the net sales for Abraxane to be approximately $1.18 billion for 2021. Based on this figure and the terms of the CVR Agreement, BMY will pay approximately $4.53 million to the trustee. This payment will then be distributed to eligible CVR holders of record as of March 6, 2022, resulting in a payment of roughly $0.1046 per CVR. This event is a direct consequence of the performance of a key acquired asset and provides clarity on the final payouts associated with this part of the Celgene deal.